Dengue Vaccines Market Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

 

Dengue Vaccines Market
Dengue Vaccines Market

To enhance tetravalent protection, sequential immunisation in addition to a heterologous prime-boost approach is gaining popularity. Companies operating in the global dengue vaccine market are likely to collaborate with scientists at organisations like the Singapore-MIT Alliance for Research and Technology (SMART), who are seizing the chance to make sequential vaccination safer and more effective than the current tetravalent vaccine.

One of the most crucial strategies for getting a competitive edge in the market for dengue vaccines globally is investing in vaccine R&D. There is a good chance that continuing research will assist in the creation of next-generation vaccines for TB, dengue, and malaria. Over the forecast period, rising dengue prevalence is anticipated to fuel dengue vaccines market expansion. For instance, between epidemiological week 1 and epidemiological week 22 of 2019, the Pan American Health Organization reported a total of 1,191,815 cases of dengue, of which 546,589 were laboratory-confirmed and 5,599 were categorised as severe dengue.

Additionally, research and development of live attenuated vaccines is anticipated to support market expansion. For instance, Dengvaxia was licenced by the U.S. FDA in May 2019 to prevent dengue infection brought on by any serotype of the dengue virus. It is a chimaera vaccine that is live attenuated, tetravalent, and created using recombinant DNA.

Comments

Popular posts from this blog

Market Share and Revenue Analysis of the Microdermabrasion Devices Market

The Role of the Foodservice Industry in Driving the French Fries Market

The Growing Demand for Healthcare Staffing Market: Trends and Opportunities